Investor demand for Elon Musk’s brain-computer interface startup, Neuralink, has driven secondary market valuations to between $29 billion and $42 billion, with aggressive bidders testing price levels near $60 billion. This pricing represents an approximately fivefold increase from the company’s last publicly disclosed funding round, which established a nine billion dollar valuation. Because Neuralink remains a private enterprise, these figures reflect transactions on secondary markets where early stakeholders and employees offload shares, rather than formal capital raises. The surge in private market pricing closely mirrors the broader appetite for exposure to Musk’s expanding technology portfolio. Following the recent public listing of SpaceX, which established a market capitalization near $1.6 trillion, private investors have demonstrated a willingness to absorb significant premiums to gain entry into the entrepreneur’s remaining ventures. Market participants report sustained inquiries for Neuralink equity, though consensus remains fragmented given the steep premium required for secondary acquisitions. Neuralink’s operational trajectory continues to anchor long-term investor confidence. The company has successfully implanted its wireless brain-machine interface devices in twenty-one clinical trial participants this year. These implants are designed to enable paralysis patients to operate digital interfaces through neural signals, with subsequent phases targeting visual restoration. Despite the absence of an official funding round announcement, sovereign wealth involvement was confirmed in May when Oman disclosed a strategic investment at an undisclosed valuation. While secondary transactions highlight robust institutional and retail interest, analysts caution that these price points are driven by speculative demand rather than fundamental revenue metrics. The company has not provided commentary on current valuation ranges or near-term capital strategy. As private markets increasingly price technology ventures on future ecosystem integration rather than current financials, Neuralink’s trajectory will likely remain sensitive to clinical trial outcomes and broader sentiment surrounding Musk’s cross-company synergies. The startup’s progression from experimental neurotechnology to commercially viable neural interfaces will ultimately determine whether current premium valuations are sustained or corrected in subsequent funding cycles.